Company news

Starpharma Holdings Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Application for quotation of securities - SPL

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 21, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 21, 2026

Starpharma secures majority ownership of Petalion

October 19, 2026

Starpharma secures majority ownership of Petalion

October 19, 2026

Trading Halt

October 15, 2026

S&P DJI Announces September 2026 Quarterly Rebalance

September 4, 2026

FY26 Key Financial Results and Annual Report

August 25, 2026

Preliminary Final Report

August 25, 2026

Successful Completion of $32 million Entitlement Offer

August 10, 2026

Entitlement Offer Investor Presentation

July 14, 2026

Fully Underwritten Entitlement Offer to Raise $32 Million

July 14, 2026

Quarterly Activities Report and Appendix 4C

July 14, 2026

DEP milestone triggers partner option fee

July 2, 2026

Positive DEP HER2-Lu preclinical data support Phase 1 entry

July 1, 2026

DEP radiopharmaceutical data supports patent application

July 1, 2026

FDA confirms path to DEP HER2 first-in-human study

April 21, 2026

Half Yearly Report and Accounts

February 17, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 28, 2026

AGM Chair address and CEO presentation

November 14, 2025

Upfront payment of USD $5.5 million received from Genentech

October 21, 2025

SPL: Research & Option Agreement with Radiopharm Theranostics

September 30, 2025

Starpharma Announces a Collaboration and License Agreement with Genentech

September 22, 2025

Presentation to Accompany License Agreement with Genentech

September 21, 2025

Starpharma Announces License Agreement with Genentech

September 21, 2025

$3.7M R&D Tax Incentive Received

August 27, 2025

FY25 Key Financial Results and Annual Report

August 26, 2025

2025 Appendix 4E Preliminary Financial Report

August 26, 2025

SPL receives positive FDA feedback on DEP SN38 for PROC

December 18, 2024

AGM Chair's address and CEO's presentation

November 26, 2024

SPL7013 Nasal Spray Australia Update

October 17, 2024

Starpharma Receives $5.5M R&D Tax Incentive Refund

September 11, 2024

Annual Report to shareholders

August 21, 2024

Positive final DEP irinotecan Phase 2 clinical trial results

May 27, 2024

Starpharma Business Update

May 22, 2024

Starpharma and Medicxi Partnership Petalion Therapeutics

April 7, 2024

S&P DJI Announces March 2024 Quarterly Rebalance

March 1, 2024

VivaGel BV US FDA Appeal Outcome

February 18, 2024

Viraleze shows antiviral efficacy in COVID-19 patients

January 28, 2024

VivaGel BV sales and distribution agreement MENA region

January 22, 2024

Positive DEP docetaxel Phase 2 results

December 18, 2023

AGM Chairman's address and CEO presentation

November 29, 2023

Starpharma announces new CEO, Ms Cheryl Maley

November 9, 2023

Starpharma receives $7.2 million R&D Tax Incentive refund

October 22, 2023

Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer

October 17, 2023

DEP irinotecan clinical data presented at AACR meeting

October 15, 2023

DEP irinotecan combination data presentation

September 26, 2023

VIRALEZ UK COVID-19 Clinical Study Completes Recruitment

September 25, 2023

Positive DEP irinotecan clinical results presentation

September 13, 2023

App 4E/Annual Report to shareholders

August 23, 2023

Older news releases →

Decks

The 5 newest of 49 decks. Every deck is listed under its year.